Astria Therapeutics (ATXS) Competitors $6.20 +0.39 (+6.71%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$6.30 +0.10 (+1.55%) As of 07/7/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATXS vs. GPCR, CVAC, CALT, AUPH, BGM, NAGE, AMPH, DYN, ABCL, and PAHCShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Structure Therapeutics (GPCR), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), BGM Group (BGM), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Astria Therapeutics vs. Its Competitors Structure Therapeutics CureVac Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals BGM Group Niagen Bioscience Amphastar Pharmaceuticals Dyne Therapeutics AbCellera Biologics Phibro Animal Health Structure Therapeutics (NASDAQ:GPCR) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation. Do insiders & institutionals hold more shares of GPCR or ATXS? 91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are owned by institutional investors. 9.4% of Structure Therapeutics shares are owned by insiders. Comparatively, 4.5% of Astria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, GPCR or ATXS? Structure Therapeutics has a beta of -1.87, suggesting that its share price is 287% less volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Which has preferable earnings & valuation, GPCR or ATXS? Structure Therapeutics is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$0.87-21.53Astria TherapeuticsN/AN/A-$94.26M-$1.87-3.32 Does the media prefer GPCR or ATXS? In the previous week, Astria Therapeutics had 4 more articles in the media than Structure Therapeutics. MarketBeat recorded 7 mentions for Astria Therapeutics and 3 mentions for Structure Therapeutics. Astria Therapeutics' average media sentiment score of 0.51 beat Structure Therapeutics' score of 0.51 indicating that Astria Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Astria Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is GPCR or ATXS more profitable? Structure Therapeutics' return on equity of -16.35% beat Astria Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -16.35% -15.71% Astria Therapeutics N/A -47.18%-31.26% Do analysts rate GPCR or ATXS? Structure Therapeutics presently has a consensus price target of $76.17, suggesting a potential upside of 306.66%. Astria Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 383.87%. Given Astria Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Astria Therapeutics is more favorable than Structure Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 SummaryAstria Therapeutics beats Structure Therapeutics on 9 of the 14 factors compared between the two stocks. Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$327.88M$2.91B$5.52B$9.02BDividend YieldN/A2.44%5.24%4.08%P/E Ratio-3.3220.3027.1920.04Price / SalesN/A250.25413.81108.84Price / CashN/A41.7026.2128.59Price / Book1.567.397.925.55Net Income-$94.26M-$55.04M$3.17B$248.49M7 Day Performance14.18%2.51%1.78%4.87%1 Month Performance3.51%-0.21%1.26%6.63%1 Year Performance-33.69%3.41%33.30%20.38% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics1.9262 of 5 stars$6.20+6.7%$30.00+383.9%-31.7%$327.88MN/A-3.3230News CoverageGPCRStructure Therapeutics2.6612 of 5 stars$20.74-1.6%$76.17+267.2%-50.4%$1.21BN/A-23.84136CVACCureVac4.4951 of 5 stars$5.43+0.9%$6.83+25.8%+64.4%$1.21B$579.18M5.90880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals2.9 of 5 stars$8.47-2.0%$11.50+35.8%+33.2%$1.17B$235.13M30.25300BGMBGM GroupN/A$10.59-11.5%N/AN/A$1.16B$25.10M0.00298News CoverageAnalyst DowngradeNAGENiagen Bioscience1.2905 of 5 stars$14.41+1.3%$19.50+35.3%N/A$1.12B$99.60M84.76120AMPHAmphastar Pharmaceuticals4.4243 of 5 stars$22.96-0.5%$32.33+40.8%-39.4%$1.09B$731.97M8.322,028DYNDyne Therapeutics3.4607 of 5 stars$9.52-0.5%$41.13+332.0%-76.2%$1.09BN/A-2.65100ABCLAbCellera Biologics2.415 of 5 stars$3.43-5.0%$8.33+143.0%+49.8%$1.08B$28.83M-6.12500News CoverageAnalyst ForecastHigh Trading VolumePAHCPhibro Animal Health3.6636 of 5 stars$25.54-0.5%$21.80-14.6%+77.4%$1.04B$1.02B32.741,940News CoverageAnalyst UpgradeGap Up Related Companies and Tools Related Companies Structure Therapeutics Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Aurinia Pharmaceuticals Competitors BGM Group Competitors Niagen Bioscience Competitors Amphastar Pharmaceuticals Competitors Dyne Therapeutics Competitors AbCellera Biologics Competitors Phibro Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXS) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredInstant Cash (in 4 clicks)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
